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Chronic mitral regurgitation (MR) is most often caused by
degenerative disease that results in prolapse, ruptured chor-
dae or partial flail leaflet. With few exceptions, patients with
chronic severe MR and symptoms of heart failure and/or left
ventricular (LV) dysfunction are candidates for mitral valve
repair or replacement (1). However, the indications for such
surgery in asymptomatic patients, especially those with
normal LV function, remain controversial and depend on a
variety of factors such as valve repairability and atrial
fibrillation. Many clinicians argue that since there are no
symptoms to improve, early surgery not only exposes the
patient to perioperative morbidity and mortality, but if
repair of the native diseased valve cannot be achieved, the
patient will also be exposed to the long-term complications
of a prosthetic valve. Thus, many clinicians are reluctant to
consider surgical correction of chronic MR in an asymp-
tomatic patient. Medical therapy with a vasoactive drug,
were it able to obviate or delay the need for surgery, would
obviously be desirable. Unfortunately, there is a persistent
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uncertainty about the utility of vasodilator therapy in
asymptomatic patients with chronic MR. In this issue of the
Journal, Perry et al. (2) report their experience with an
angiotensin II type-1 (AT1) receptor blocking agent in an
experimental model of MR. This work, coupled with
previous research by these investigators (3), sounds a cau-
tionary note that should influence clinicians and investiga-
tors in their efforts to assess and evaluate the LV response,
the hemodynamics and the management of MR.
The LV response. Mitral regurgitation burdens the left
ventricle with a volume load that leads to a series of
compensatory myocardial and circulatory adjustments (4–
6). These adjustments vary over a prolonged course; changes
that are operative in acute MR are eventually replaced by
other compensatory mechanisms. With acute MR and
volume overload, the ventricle draws on preload reserve and
the total stroke volume increases via the Frank-Starling
mechanism. In addition, the low resistance runoff into the
left atrium contributes to an increased ejection fraction and
a decrease in systolic volume; according to the law of
Laplace, systolic load (i.e., afterload) declines. Thus, in
acute MR, an increased ejection fraction and increased total
stroke volume occur as a result of an increase in LV preload
and a decrease in afterload.
The major change that occurs during the evolution from
acute to chronic MR is an enlargement of the ventricle. As
this new state develops, the small hyperkinetic chamber of
acute MR is converted to a large compliant chamber that is
well suited to deliver a large stroke volume. This comes
about through a dissolution of collagen weave and remod-
eling of the extracellular matrix with a rearrangement of
myocardial fibers, in association with the addition of new
sarcomeres and the development of eccentric LV hypertro-
phy. As a result, cardiomyocytes are longer (2,3) but preload
at the sarcomere level (i.e., sarcomere length) returns toward
normal (4). Moreover, the systolic unloading that is char-
acteristic of acute MR is gradually replaced by normal
systolic wall stresses (5). Thus, the enhanced total stroke
volume, seen in chronic compensated MR, is “mediated
through a normal performance of each unit of an enlarged
circumference” (6). At this time, LV contractility and
ejection fraction are normal and total stroke volume is high
as a result of the large end-diastolic volume. The experi-
mental model used by Perry et al. (2) closely resembles this
chronic compensated state (i.e., severe MR with LV en-
largement and normal systolic function). During this com-
pensated phase of the disease, most patients remain asymp-
tomatic. This would seem to be an ideal time for the use of
vasodilator therapy—if such treatment could reliably reduce
the volume overload and thereby protect the ventricle from
progressive enlargement and decompensation.
The most elusive and poorly understood aspect of the
pathophysiology of MR is the nature of the transition from
the compensated to a decompensated state. This may occur
as a consequence of progressive increments in the regurgi-
tant volume, or a gradual depression of myocardial contrac-
tility or both. The decompensated state is characterized by
substantial and progressive ventricular enlargement, high
LV diastolic pressure and wall stress, increased systolic wall
stress and a decline in the ejection fraction. The fall in
ejection fraction is a consequence of both depressed LV
contractile state and afterload excess. Progressive atrial
enlargement and atrial arrhythmias are seen, pulmonary
hypertension develops and the patient becomes symptom-
atic. At this late (i.e., decompensated) stage, there may be
irreversible depression of ventricular and atrial function and
although some patients may benefit from surgery, an opti-
mal surgical result is unlikely.
Ventricular afterload. As mentioned previously, LV sys-
tolic wall stresses are reduced in acute MR, but subsequently
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revert to normal as the ventricle enlarges and adapts to the
volume overload. Eventually systolic wall stresses may ex-
ceed normal, and in decompensated MR an afterload excess
contributes to the decline in ejection fraction. Despite
evidence to the contrary, the notion persists that afterload is
low in chronic MR. Several published studies refute this
misconception (5,7–11). Using echocardiographic measures
of LV volume, mass and geometry, Zile et al. (8) found that
meridional end-systolic stress was normal in compensated
MR and increased in decompensated MR; they also found
a tendency for peak systolic stress to be increased in both.
Corin et al. (9) later confirmed these observations with
cardiac catheterization techniques. They calculated circum-
ferential wall stress and found a modest increase in peak
systolic stress in compensated and decompensated ventri-
cles; end-systolic stress was particularly high in decompen-
sated ventricles. Likewise Wisenbaugh et al. (10) and
Carabello et al. (11) described normal or increased afterload
in patients with chronic MR. Perry et al. (2) also confirm
elevated peak systolic stress with values for end-systolic
stress that are significantly higher than normal. These and
other similarities between their experimental model and
MR in humans help validate their work as relevant to
human disease.
Hydraulic determinants of regurgitant flow. The deter-
minants of mitral regurgitant volume are best understood in
the context of the orifice equation. This equation, based on
the Torricelli principle, states that flow through an orifice
varies by the square root of the pressure gradient across that
orifice:
MRV  MROA  C  TS  LVP LAP
where MRVmitral regurgitant volume, MROAmitral
regurgitant orifice area, C  constant, Ts  time or
duration of systole, LVP  LV mean systolic pressure and
LAP  left atrial mean systolic pressure. In many if not
most patients with MR, the regurgitant orifice area is
dynamic with variations that are dependent on LV geome-
try. The systolic pressure gradient across the valve also can
vary dramatically. These two determinants of regurgitant
volume are the primary therapeutic targets in patients with
MR and vasodilators have the potential to affect both. It
should be emphasized that systemic vascular resistance, LV
systolic wall stress (i.e., afterload) and contractile or inotro-
pic state are not direct determinants of the regurgitant
volume, and in asymptomatic patients who might be can-
didates for vasodilator therapy are not primary therapeutic
targets.
The severity of regurgitation. Left ventricular cineangiog-
raphy and Doppler echocardiography are widely used to
evaluate the severity of MR, but these methods are only
semiquantitative (12). Calculations of the regurgitant vol-
ume or fraction with catheterization or echocardiographic
techniques are more accurate (13), but the methods require
careful attention to detail and until recently had not been
widely applied. Moderate MR is said to be present when the
regurgitant fraction is in the range of 30% to 50%; severe
MR is defined as a regurgitant fraction 50%. It should be
noted, however, that the regurgitant fraction varies inversely
with the total stroke volume and that an increase in the LV
end-diastolic volume and/or ejection fraction might reduce
significantly the regurgitant fraction—despite a constant
regurgitant volume. The magnitude of the regurgitant
volume, and its relation to the end-diastolic volume, can be
of signal importance in clinical decision making.
Clinical vasodilator studies. The short-term effects of
vasodilator therapy in patients with chronic MR have been
variable and dependent, among other factors, on the agent
employed (14). For example, nitroprusside has produced a
consistent decrease in the regurgitant volume and an in-
crease in forward stroke volume, generally accompanied by
a reduction in end-diastolic pressure and volume. Nitroglyc-
erin tends to produce a reduction in end-diastolic volume
with little effect on regurgitant volume or forward stroke
volume. The short-term effects of angiotensin-converting
enzyme (ACE) inhibitors appear to be less consistent, but
there is a tendency for regurgitant volume to decrease
during such treatment.
The long-term use of vasodilator therapy in chronic MR
has virtually been limited to ACE inhibitors and AT1
receptor blockers (14–17). In three recently published
studies, the use of these agents produced a decrease in the
regurgitant volume, but the average changes were relatively
small and there were substantial individual variations in the
magnitude of the effect (15–17). A decrease in end-diastolic
volume was not uniformly seen (15), and exercise tolerance
was not improved (15,16). In one blinded study, therapy
was withdrawn from one-third of the patients because of
side effects (15); another study that was not blinded did not
include information on the patients’ symptoms (17); another
did not relate the observed changes to the baseline LV size
and function or the severity of regurgitation (16). These and
other limitations, including small numbers of patients stud-
ied, should limit the enthusiasm for the use of ACE
inhibitors or AT1 receptor blockers in nonhypertensive
asymptomatic patients with chronic MR. Nevertheless,
these agents are commonly employed in patients with MR
(18).
Experimental studies. Dell’Italia et al. (3) have previously
shown that treatment with an ACE inhibitor (resulting in a
reduction in LV angiotensin II levels to normal) failed to
attenuate the LV remodeling, enlargement and hypertro-
phy. The loss of collagen weave, seen in their model of MR,
was not affected by the ACE inhibitor, nor was the increase
in cardiomyocyte length (3). Based on their observations of
“normal” LV angiotensin II levels and the upregulation of
AT1 receptors, they suggested that an AT1 receptor block-
ade (alone or in combination with an ACE inhibitor) might
be effective in preventing the observed pathophysiologic
consequences.
In this issue of the Journal, Perry et al. (2) studied the
effects of AT1 receptor blockade on hemodynamics, LV size
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and function and cardiomyocyte length in dogs with MR.
Their experimental model is well established (2,3,19), and it
resembles severe degenerative mitral valve disease in humans
(i.e., chordal rupture and flail leaflet with regurgitant frac-
tion exceeding 50%). By initiating therapy with AT1 recep-
tor blockade at the onset of MR, they were able to assess the
effects of a blockade that was present during and after the
early adaptation to severe MR. At three months, a substan-
tial vasodilator effect was seen; systemic resistance and LV
systolic pressure were significantly lower in the treated than
in the untreated group with MR. Despite these favorable
vasodilator effects, regurgitant volume remained high and
importantly, the eccentric remodeling with ventricular en-
largement and cardiomyocyte lengthening was not reversed.
Indeed, there was a tendency for end-diastolic and end-
systolic volumes and cardiomyocyte length to be greater in
the treated group than in the untreated group. Left ventric-
ular angiotensin levels are elevated in this model of MR, and
treatment with AT1 receptor blockers reduced the LV
angiotensin II levels to normal. This result is similar to that
previously observed with ACE inhibition, and the authors
conclude that blockade of the renin-angiotensin system
promotes dissolution of collagen weave and thereby contrib-
utes to increased ventricular size and cardiomyocyte length.
Comment. Severe MR, resulting in LV volume overload
and high diastolic wall stress, induces a collagen degradation
state with a remodeling of the extracellular matrix that
fosters an adaptive LV enlargement. By treating the animals
with an AT1 receptor blocking agent during the early
adaptive phase (at the onset of MR), Perry et al. (2) further
weakened the collagen weave thereby offsetting any benefi-
cial effect on LV size that might be produced by vasodila-
tion. In addition to these actions of ACE inhibitors and
AT1 receptor blockers on the LV interstitium, it is possible
that a similar deleterious effect is present in prolapsing
mitral leaflets (20). It is also plausible that the alterations in
the extracellular matrix and ventricular remodeling are
influenced by the chymase system and the matrix metallo-
proteinases, and that their activities as well as those of the
cardiac renin-angiotensin system interact and vary over the
time course of the disease. Initiation of therapy at a later
time (i.e., during the chronic compensated phase) might
very well produce a different effect on the LV; such “late”
data would appear to be more relevant to humans with
chronic MR and should be a high priority for future studies.
Returning to the orifice equation (vide supra), at a
constant regurgitant orifice area a modest reduction in the
systolic pressure gradient between the ventricle and the
atrium would be expected to have minimal impact on
regurgitant volume. Indeed, this was the case in the work by
Perry et al. (2) in which a 10% to 15% decrease in the
pressure gradient would be expected to produce only a 7%
reduction (3 to 4 ml) in regurgitant volume. Such a small
change is unlikely to be detected with the currently available
techniques; Perry et al. (2) did not detect a change. It is
possible, therefore, that the persistent LV enlargement was
related to the persistence of a large regurgitant volume in a
ventricle with a weakened extracellular matrix.
It is also noteworthy that LV end-systolic dimension
increased and systolic pressure decreased more in the ani-
mals treated with AT1 receptor blockade than in the
untreated MR group. These and other data reported by
Perry et al. (2) suggest a relative decrease in contractile
function with AT1 receptor blockade. Such blockade could
blunt the angiotensin II promotion of catecholamine release
into the interstitium and thereby produce a depression of
contractility (21). The tendency for contractile function to
decline requires further research.
Conclusions and future directions. The time for ACE
inhibitors and AT1 receptor blocking agents to be regarded
as mere vasodilators is long past. Certainly the vasoactive
properties are important, but the tissue activity of the
renin-angiotensin system is critically related to the structural
and functional alterations that occur in the ventricle during
its adaptation to volume overload. It cannot be assumed that
ACE inhibitors or AT1 receptor blockers invariably protect
the heart—particularly during the early phases of MR. The
interactive effects of the renin-angiotensin, the chymase and
the matrix metalloproteinase systems during the early adap-
tive and later phases of MR obviously warrant further study.
While no one would argue against the use of ACE
inhibitors or perhaps AT1 receptor blockers in myopathic
hearts with secondary MR, the available human data do not
provide strong support for the use of the agents in asymp-
tomatic patients with valvular MR and normal LV function.
When a compelling indication (e.g., hypertension, diabetes)
exists for the use of ACE inhibitors or AT1 receptor
blockers in a patient with coexisting MR, these drugs can
obviously be used. However, a long-term beneficial effect on
the regurgitant lesion should not necessarily be expected and
most importantly, such therapy should not replace careful
clinical follow-up including periodic evaluation of the mitral
structure, the severity of regurgitation, as well as LV size
and function (1). The provocative study of Perry et al. (2)
coupled with a limited published clinical experience, pro-
vides strong rationale for a well designed clinical trial that
incorporates information on LV size and function, and
especially clinical outcome.
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